Glycation Interferes with the Expression of Sialyltransferases in Meningiomas.

Philipp Selke,Tao Zhang,Christian Strauss,Kaya Bork,Rüdiger Horstkorte,Maximilian Scheer,Manfred Wuhrer

doi:10.3390/cells10123298

Abstract

Meningiomas are the most common non-malignant intracranial tumors and prefer, like most tumors, anaerobic glycolysis for energy production (Warburg effect). This anaerobic glycolysis leads to an increased synthesis of the metabolite methylglyoxal (MGO) or glyoxal (GO), which is known to react with amino groups of proteins. This reaction is called glycation, thereby building advanced glycation end products (AGEs). In this study, we investigated the influence of glycation on sialylation in two meningioma cell lines, representing the WHO grade I (BEN-MEN-1) and the WHO grade III (IOMM-Lee). In the benign meningioma cell line, glycation led to differences in expression of sialyltransferases (ST3GAL1/2/3/5/6, ST6GAL1/2, ST6GALNAC2/6, and ST8SIA1/2), which are known to play a role in tumor progression. We could show that glycation of BEN-MEN-1 cells led to decreased expression of ST3Gal5. This resulted in decreased synthesis of the ganglioside GM3, the product of ST3Gal5. In the malignant meningioma cell line, we observed changes in expression of sialyltransferases (ST3GAL1/2/3, ST6GALNAC5, and ST8SIA1) after glycation, which correlates with less aggressive behavior.

Highlights

Published: 25 November 2021Meningiomas arise from the arachnoid and are the most common non-malignant intracranial tumor [1,2,3,4,5]
Since there is evidence that sialyltransferases have an impact on tumorigenesis, we analyzed benign (BEN-MEN-1) and malignant (IOMM-Lee) meningioma cell lines regarding differences in expression of sialyltransferases (Figure 2, Table 1)
ST3GAL5–ST3GAL6 were detected in both cell lines

Summary

Introduction

Meningiomas arise from the arachnoid and are the most common non-malignant intracranial tumor [1,2,3,4,5]. They are classified according to WHO (World Health Organization) in grades I, II, and III. The benign grade I represents the most frequent subtype (>80%), and has a low risk of recurrence and slow growth [5,6]. As opposed to benign meningioma, grade III meningiomas (anaplastic, rhabdoid, and papillary subtype) are rare (1–3%) and little is known about factors that influence their survival and malignity. The present surgical, medicinal, and radiotherapeutic treatments are not adequate to manage the morbidity and mortality in this subtype [7,8,9,10].

Results

Discussion

Conclusion